Back

It is time to reconsider aspirin as a routine therapy for secondary prevention after STEMI - CONTRA.

4 March 2018 (15:00 - 15:15)
Organised by:
Congress Presentation Part of: Great debate on STEMI: current controversies on antiplatelet management after the acute phase Acute Coronary Syndromes: Post-Infarction Period Open Access Acute Cardiovascular Care 2018

About the speaker

Photo
Professor Freek Verheugt

Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam (Netherlands (The))

9 More presentations in this session

Presentation thumbnail
Risk scores are helpful for defining optimal DAPT duration - PRO.
Professor S. De Servi (Pavia, IT)
Slides Video
Presentation thumbnail
Risk scores are helpful for defining optimal DAPT duration - CONTRA.
Professor A. Budaj (Warsaw, PL)
Slides Video
Presentation thumbnail
Risk scores are helpful for defining optimal DAPT duration - Rebuttal PRO.
Professor S. De Servi (Pavia, IT)
Video
Presentation thumbnail
Risk scores are helpful for defining optimal DAPT duration - Rebuttal CONTRA.
Professor A. Budaj (Warsaw, PL)
Presentation thumbnail
Risk scores are helpful for defining optimal DAPT duration: Chairpersons conclusion.

Access the full session

Session thumbnail
Great debate on STEMI: current controversies on antiplatelet management after the acute phase

The Event

Event poster

Acute Cardiovascular Care 2018

4 March 2018 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Antithrombotic prescription in secondary cardiovascular prevention: are we following the guidelines?
4 April 2025
thumbnail
Congress Presentation
Discussant review - PREMIUM
29 August 2026
thumbnail
Congress Presentation
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction
27 August 2022
thumbnail
Congress Presentation
Reevaluated role of outpatient cardiovascular rehabilitation on clinical outcomes after acute myocardial infarction: a meta-analysis of European randomized clinical trials
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources